AiOra has launched its 5th Quarter supplement range featuring three unique blends that harness nutritionally rich animal products often overlooked in modern diets.
Cibus Fund, advised by ADM Europe, has agreed to invest in PharmaZen for at least three years.
Jan 19, 2021
Biotechnology company PharmaZen has raised $14.0 million from an international agri-technology fund to expand its operations amid surging global demand for its nutraceutical products. The company’s portfolio of ingredients covers joint, bone, muscle and digestive health, along with marine and bovine collagen and animal nutrition. Many of these value-added ingredients are byproducts of the food industry that would otherwise go to waste, improving the efficiency of food production.
The Cibus Fund, advised by ADM Capital Europe, invests growth capital into sustainably run food and agriculture companies across the globe. The Cibus Fund has agreed to invest for at least three years and to work with existing management to invest this capital in new facilities to accelerate growth.
Products sold under Pharmazen’s Aiora range include supplements to promote eye, bone, joint and gut health. The company already employs 50 people at its Christchurch base in Port Hills Rd, and work on the first of two new 3000 square metre factories in Rolleston will begin next month. The first factory costing $5.5m is expected to be completed in August to house three large freeze dryers as well as new extraction facilities and an expanded marine collagen plant. PharmaZen is also planning to exercise its option to purchase another neighbouring Rolleston site for a second factory that will make high value pet treats.